HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 4, 2022-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a $20 million equity investment by Hanmi Pharmaceutical along with revisions to the licensing agreements for

Fast Track application is based on positive data in NSCLC HER2 exon 20 insertion mutations in previously treated patients Positive Results for Cohort 2 of ZENITH20 clinical trial published in Journal of Clinical Oncology HENDERSON, Nev. --(BUSINESS WIRE)--Dec.

Tom Riga named President and Chief Executive Officer and will join the Board of Directors effective December 31, 2021 Joe Turgeon , President and Chief Executive Officer, to retire and step down from Board of Directors HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 1, 2021-- Spectrum Pharmaceuticals, Inc.

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 30, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the JMP Securities Hematology and Oncology Summit, a virtual presentation

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 11, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the 2021 Jefferies London Healthcare Conference .

Poziotinib NDA is on track for submission in 2021 under a Fast Track designation Positive front line poziotinib data presented at ESMO Congress 2021 from Cohort 4 of the ZENITH20 clinical trial Preclinical data presented at 2021 AACR-NCI-EORTC (Triple) conference demonstrated the synergistic impact

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 3, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2021 financial results and provide a corporate

HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 7, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of preclinical data demonstrating the synergistic impact of poziotinib when combined with KRAS

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 22, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the 2021 Cantor Virtual Global Healthcare Conference .

Early data from Cohort 4 of the ongoing ZENITH20 clinical trial shows ORR of 44% in 48 first-line patients treated with 16mg of poziotinib once daily HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 18, 2021-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 13, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a late-breaking presentation of early poziotinib efficacy and safety data in first-line patients with non-small

Submission of poziotinib NDA on track for later in 2021 under a Fast Track designation The company is requesting a meeting with the FDA to clarify the remediation timelines regarding the Complete Response Letter (CRL) for ROLONTIS ® (eflapegrastim) Management to host webcast and conference call

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 6, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 5, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2021 financial results and provide a corporate

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 4, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented an e-poster on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations.

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 1, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) is “on site” for the ROLONTIS® (eflapegrastim) manufacturing

HENDERSON, Nev. --(BUSINESS WIRE)--May 28, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations.

HENDERSON, Nev. --(BUSINESS WIRE)--May 27, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at

Poziotinib NDA on track for 2021 submission New poziotinib twice daily dosing (BID) data presented at AACR demonstrated improved anti-tumor activity and better tolerance FDA pre-approval inspection at the ROLONTIS ® manufacturing facility scheduled for May 2021 Management to host webcast and

HENDERSON, Nev. --(BUSINESS WIRE)--May 6, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2021 financial results and provide a corporate update